You just read:

C2N and AbbVie Announce FDA Orphan Drug Designation of C2N-8E12 (ABBV-8E12) for the Treatment of Progressive Supranuclear Palsy

News provided by

AbbVie Inc.

Jul 17, 2015, 08:01 ET